Momenta Pharmaceuticals (MNTA) Price Target Raised to $25 at Brean Capital Following 'Big Win'
Tweet Send to a Friend
Brean Capital analyst Difei Yang reiterated a Buy rating and raised his price target on Momenta Pharmaceuticals (NASDAQ: MNTA) to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE